Stock Performance Review on Biotech Industry -- Intrexon, Ampio Pharma, AmpliPhi Biosciences, and CorMedix

NEW YORK, September 19, 2017 /PRNewswire/ --

If you want a Stock Review on XON, AMPE, APHB, or CRMD then come over to and sign up for your free customized report today. On Monday, the NASDAQ Composite ended the day at 6,454.64, up 0.10%; the Dow Jones Industrial Average edged 0.28% higher, to finish at 22,331.35; and the S&P 500 closed at 2,503.87, marginally gaining 0.15%. US markets saw four out of nine sectors finishing the day in green, 2 in red, and 3 in neutral territory. has initiated research reports on the following Biotechnology stocks: Intrexon Corp. (NYSE: XON), Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE), AmpliPhi Biosciences Corp. (NYSE MKT: APHB), and CorMedix Inc. (NYSE MKT: CRMD). Daily Stock Tracker published comprehensive and free research reports on these stocks today at:


Germantown, Maryland-based Intrexon Corp.'s stock finished Monday's session 0.52% higher at $19.47 with a total trading volume of 673,895 shares. The stock has gained 10.50% in the past month. The Company's shares are trading below their 50-day moving average by 5.87%. Moreover, shares of Intrexon, which operates in the synthetic biology field in the US, have a Relative Strength Index (RSI) of 46.29. XON complete research report is just a click away and free at: Ampio Pharmaceuticals 

Shares in Englewood, Colorado headquartered Ampio Pharmaceuticals Inc. rose 6.73%, ending yesterday's session at $0.56 with a total trading volume of 383,585 shares. The stock has gained 44.91% in the past month. The Company's shares are trading above their 50-day moving average by 8.33%. Moreover, shares of Ampio Pharma, which focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the US, have an RSI of 58.81. The complimentary report on AMPE can be downloaded at: AmpliPhi Biosciences 

On Monday, San Diego, California headquartered AmpliPhi Biosciences Corp.'s stock saw a rise of 0.99%, to close the day at $1.02. A total volume of 315,888 shares was traded. The Company's shares have advanced 31.44% in the last one month and 27.48% in the previous three months. The stock is trading above its 50-day moving average by 13.64%. Additionally, shares of AmpliPhi Biosciences, which focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology, have an RSI of 61.17.

On August 28th, 2017, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, with a target price of $5 per share. Sign up for your complimentary research report on APHB at: CorMedix 

Shares in Bridgewater, New Jersey-based CorMedix Inc. ended the day flat at $0.42. A total volume of 687,307 shares was traded. The Company's shares are trading above their 50-day moving average by 3.66%. Furthermore, shares of CorMedix, which focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the US and other markets, have an RSI of 48.93.  Get free access to your research report on CRMD at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA(R) charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



        For any questions, inquiries, or comments reach out to us directly. If you're a company
         we are covering and wish to no longer feature on our coverage list contact us via
         email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:  
        Phone number: (207)331-3313 
        Office Address: 377 Rivonia Boulevard, Rivonia, South Africa  


CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.